Bactolife
Lyngby
About Bactolife
Bactolife is a biotechnology company that develops biological solutions based on proprietary binding protein technology to support gut health by targeting and neutralizing harmful microbial activity without disrupting beneficial microbiota. Its platform produces precision-designed proteins that act on specific toxins in the gastrointestinal system, enabling applications in food, feed, dietary supplements, and health ingredients for humans and animals. Bactolife’s innovations aim to reduce the risk of gastrointestinal infections and decrease reliance on traditional antibiotics by offering alternative mechanisms that strengthen the microbiome. The company collaborates with partners to advance product development, conduct clinical studies, and scale manufacturing for broader market delivery. Users of its technology include product developers, nutrition brands, and animal health stakeholders seeking science-based gut health solutions. Bactolife continues to expand its ingredient offerings and global deployment of its Binding Protein platform to address emerging health and microbiome needs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $81.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2026)
- Website: bactolife.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/bactolife-15933 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.